04/10/2024
5:10 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
04/01/2024
5:15 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
03/27/2024
5:34 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/09/2024
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/06/2024
8:36 AM | BlackRock Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/05/2024
5:24 AM | Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/02/2024
5:16 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
02/01/2024
5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024
5:06 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/25/2024
5:13 AM | Phathom Pharmaceuticals, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:11 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
01/19/2024
5:03 AM | Equillium, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13G | |
01/16/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/14/2023
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/30/2023
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/13/2023
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023
5:22 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023
5:21 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/02/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/28/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/11/2023
5:50 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2023
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/27/2023
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/12/2023
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2023
5:26 AM | Sequeira Ramona (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:33 AM | Bitetti Teresa Marie (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:35 AM | Takeda Pharmaceutical (Subject)
Wozniewski Thomas Otto Claus (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:16 AM | Kim Julie So-Young (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:20 AM | Duprey Lauren Rusckowski (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:22 AM | Pignagnoli Agosti Marcello (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:24 AM | Lugogo Mwana Pietrina (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:06 AM | Ricci Gabriele (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:09 AM | Plump Andrew Stewart (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:12 AM | Greco Gerard M (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:14 AM | Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/06/2023
5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/03/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023
5:35 AM | Takeda Pharmaceutical (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
REVEALED: Elon Musk’s Secret A.I. Facility? (Ad) I recently shot this video outside what could be Elon Musk’s biggest secret.
What’s happening inside these walls is so important that our government has declared it a matter of national security. Click here to see the details because there’s a lot of money at stake. |
06/28/2023
5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
06/23/2023
5:13 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/23/2023
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/09/2023
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/01/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:11 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:14 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/26/2023
6:08 AM | Calithera Biosciences, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Takeda Ventures, Inc. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/26/2023
6:08 AM | Calithera Biosciences, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
05/17/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/15/2023
5:09 AM | Takeda Pharmaceutical (Filer)
| Form SD
Specialized Disclosure Report | |
05/11/2023
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/11/2023
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
